Celladon Corporation is a clinical-stage biotechnology company that specializes in developing cardiovascular gene therapy and calcium dysregulation. Its lead product candidate, MYDICAR, utilizes genetic enzyme replacement therapy to address deficiencies in the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme that contribute to heart failure. MYDICAR is intended for patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as for those with pulmonary arterial hypertension and arteriovenous fistula maturation failure.
Caledonia Investments plc's ticker is CLDN
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 51-200 employees working at Caledonia Investments plc
It is http://www.caledonia.com/
Caledonia Investments plc is in the Healthcare sector
Caledonia Investments plc is in the Biotechnology industry
The following five companies are Caledonia Investments plc's industry peers: